Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It is engaged in diabetes care. It has a range of diabetes product portfolio, including a portfolio of modern insulins and the first human once-daily GLP-1 analog. In addition, it has is engaged in areas, such as haemophilia, growth hormone therapy and hormone replacement therapy. It manufactures and markets pharmaceutical products and services to patients, the medical profession and society. The Company operates in two segments: diabetes care and biopharmaceuticals. In February 2014, Innate Pharma has acquired full development and commercialization rights to the anti-NKG2A antibody, a immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.